Duloxetine enhances stage 3 sleep in patients with major depression

M. Kluge; P. Schüssler; A. Steiger

doi:10.1055/s-2007-991716

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000054.xml

Share / Bookmark

Facebook X Linkedin Weibo

Pharmacopsychiatry 2007; 40 - A041
DOI: 10.1055/s-2007-991716

Duloxetine enhances stage 3 sleep in patients with major depression

M Kluge ¹, P Schüssler ¹, A Steiger ¹

¹Max-Planck-Institut für Psychiatrie

Congress Abstract

Sleep-EEG studies in patients with major depression receiving the new selective norepinephrine and serotonin reuptake inhibitor (SNRI) duloxetine are lacking. Therefore, polysomnographies in 10 patients with major depression (7 males, 3 females, 39.9±7.6 years, HAMD-21 score: 23.6±5.6) were recorded twice, before and after 7–14 days of treatment with duloxetine. Stage 3 sleep significantly (P<0.01) increased from 21.0±10.7 to 37.4±20.1 minutes. Rapid eye movement (REM) latency significantly (P<0.005) increased from 58.5±31.1 to 193.6±72.6 minutes. REM sleep significantly (P<0.005) decreased from 94.8±34.5 to 51.5±42.5 minutes. These results partly differ from those in healthy subjects receiving duloxetine.